Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
11 results
RMD open, Volume 9, Issue 2, 1 1 2023, Pages e002971 Step forward in early recognition of systemic sclerosis: data from the Leiden CCISS cohort. Liem SIE, Ciaffi J, van Leeuwen NM, Boonstra M, Ahmed S, Beaart-van de Voorde LJJ, Corsel A, Dhondai T, Ninaber MK, Geelhoed-Veltman JJM, Heuvers ME, Tushuizen ME, Ajmone Marsan N, Kiès P, Schouffoer AA, Huizinga TWJ, Allaart CF, De Vries-Bouwstra J
Background: Since 2009, Dutch patients with a confirmed diagnosis/suspicion of systemic sclerosis (SSc) can be referred to the Leiden Combined Care in Systemic Sclerosis (CCISS) cohort. This study evaluated whether early recognition of SSc has improved over time and whether disease characteristics and survival has changed over time. Methods: 643 SSc patients fulfilling American College of Rheumatology/European Alliance of Associations for Rheumatology 2013 SSc criteria were included and categori... Abstract
Cited 51 times since 2015 (5.6 per year) source: EuropePMC
Oncoimmunology, Volume 4, Issue 7, 19 3 2015, Pages e1014242 Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer. de Goeje PL, Bezemer K, Heuvers ME, Dingemans AC, Groen HJ, Smit EF, Hoogsteden HC, Hendriks RW, Aerts JG, Hegmans JP
Myeloid-derived suppressor cells (MDSCs) play an important role in immune suppression and accumulate under pathologic conditions such as cancer and chronic inflammation. They comprise a heterogeneous population of immature myeloid cells that exert their immunosuppressive function via a variety of mechanisms. Immunoglobulin-like transcript 3 (ILT3) is a receptor containing immunoreceptor tyrosine-based inhibition motifs (ITIMs) that can be expressed on antigen-presenting cells and is an important... Abstract
Cited 50 times since 2013 (4.6 per year) source: EuropePMC
Lung cancer (Amsterdam, Netherlands), Volume 81, Issue 3, 11 2 2013, Pages 468-474 Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients. Heuvers ME, Muskens F, Bezemer K, Lambers M, Dingemans AC, Groen HJM, Smit EF, Hoogsteden HC, Hegmans JPJJ, Aerts JGJV
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immature and progenitor myeloid cells with immunosuppressive activity that are increased in cancer patients. Until now, the characterization of MDSC in humans was very challenging. The aim of this study was to determine the characterization and optimal assessment of MDSC and to investigate their presence and function in blood of advanced-stage NSCLC patients. We determined MDSC and lymphocyte populations in peripheral bloo... Abstract
Cited 21 times since 2012 (1.8 per year) source: EuropePMC
BMC pulmonary medicine, Volume 12, 13 2 2012, Pages 77 Improving lung cancer survival; time to move on. Heuvers ME, Hegmans JP, Stricker BH, Aerts JG
Background: During the past decades, numerous efforts have been made to decrease the death rate among lung cancer patients. Nonetheless, the improvement in long-term survival has been limited and lung cancer is still a devastating disease. Discussion: With this article we would like to point out that survival of lung cancer could be strongly improved by controlling two pivotal prognostic factors: stage and treatment. This is corresponding with recent reports that show a decrease in lung cancer m... Abstract
Cited 15 times since 2012 (1.3 per year) source: EuropePMC
BMC cancer, Volume 12, 5 1 2012, Pages 580 Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. Heuvers ME, Aerts JG, Cornelissen R, Groen H, Hoogsteden HC, Hegmans JP
Cancer research has devoted most of its energy over the past decades on unraveling the control mechanisms within tumor cells that govern its behavior. From this we know that the onset of cancer is the result of cumulative genetic mutations and epigenetic alterations in tumor cells leading to an unregulated cell cycle, unlimited replicative potential and the possibility for tissue invasion and metastasis. Until recently it was often thought that tumors are more or less undetected or tolerated by... Abstract
Cited 7 times since 2012 (0.6 per year) source: EuropePMC
Immunotherapy, Volume 4, Issue 10, 1 1 2012, Pages 1011-1022 Dendritic cell-based immunotherapy in mesothelioma. Cornelissen R, Lievense LA, Heuvers ME, Maat AP, Hendriks RW, Hoogsteden HC, Hegmans JP, Aerts JG
Mesothelioma is a rare thoracic malignancy with a dismal prognosis. Current treatment options are scarce and clinical outcomes are rather disappointing. Due to the immunogenic nature of mesothelioma, several studies have investigated immunotherapeutic strategies to improve the prognosis of patients with mesothelioma. In the last decade, progress in knowledge of the modulation of the immune system to attack the tumor has been remarkable, but the optimal strategy for immunotherapy has yet to be un... Abstract
Cited 19 times since 2012 (1.6 per year) source: EuropePMC
European journal of epidemiology, Volume 27, Issue 9, 8 2 2012, Pages 669-672 Generalizability of results from the National Lung Screening Trial. Heuvers ME, Wisnivesky J, Stricker BH, Aerts JG
Lung cancer is the major cause of cancer-related death worldwide, with a 5-year survival of only 16%. Most lung cancer cases are diagnosed at an advanced incurable stage. As earlier stages have a better prognosis, the key to reducing mortality could be early diagnosis of the disease. At present, low-dose computed tomographic (CT) screening has shown promising data. Lung cancer death rates were reduced by 20% when CT screening is compared to chest radiography in a high-risk group. There are many... Abstract
Cited 9 times since 2012 (0.8 per year) source: EuropePMC
Clinical & developmental immunology, Volume 2012, 24 4 2012, Pages 927240 New roads open up for implementing immunotherapy in mesothelioma. Cornelissen R, Heuvers ME, Maat AP, Hendriks RW, Hoogsteden HC, Aerts JG, Hegmans JP
Treatment options for malignant mesothelioma are limited, and the results with conventional therapies have been rather disappointing to this date. Chemotherapy is the only evidence-based treatment for mesothelioma patients in good clinical condition, with an increase in median survival of only 2 months. Therefore, there is urgent need for a different approach to battle this malignancy. As chronic inflammation precedes mesothelioma, the immune system plays a key role in the initiation of this typ... Abstract
Cited 19 times since 2012 (1.5 per year) source: EuropePMC
Lung cancer (Amsterdam, Netherlands), Volume 76, Issue 3, 9 2 2012, Pages 452-456 History of tuberculosis as an independent prognostic factor for lung cancer survival. Heuvers ME, Aerts JG, Hegmans JP, Veltman JD, Uitterlinden AG, Ruiter R, Rodenburg EM, Hofman A, Bakker M, Hoogsteden HC, Stricker BH, van Klaveren RJ
Introduction: It is well known that pulmonary tuberculosis is associated with an increased risk of lung cancer. We investigated whether a history of pulmonary tuberculosis is an independent risk factor for lung cancer survival in Caucasian patients. Methods: The data of the prospective population-based cohort of The Rotterdam Study were used. During a mean follow-up time of 18 years, there were 214 incident cases of pathology-proven lung cancer in a source population of 7983 study participants.... Abstract
Cited 7 times since 2012 (0.6 per year) source: EuropePMC
The New England journal of medicine, Volume 366, Issue 2, 1 1 2012, Pages 192-193 Generalizing lung-cancer screening results. Heuvers ME, Stricker BH, Aerts JG
Cited 1 times since 2009 (0.1 per year) source: EuropePMC
Transplant international : official journal of the European Society for Organ Transplantation, Volume 22, Issue 9, 24 4 2009, Pages 940-942 Sirolimus-related dyspnoea, airway obstruction and pleural effusion after lung transplantation. Kan HJ, Heuvers ME, Grijm K, van Hal PT